Histologic and molecular characterization of lung cancer with tissue obtained by electromagneic navigation bronchoscopy

Journal of Bronchology and Interventional Pulmonology

Volumn 20, Issue 1, 2013, Pages 10-15

  Ha, Duc ^a   Choi, Humberto ^a   Almeida, Francisco A ^a   Arrossi, Andrea ^a   Brainard, Jennifer ^a   Cicenia, Joseph ^a   Farver, Carol ^a   Gildea, Thomas ^a   MacHuzak, Michael S ^a   Mazzone, Peter ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Echinoderm microtubule associated protein like 4 anaplastic lymphoma kinase (EML4 ALK) translocation; Electromagnetic navigation bronchoscopy; Epidermal growth factor receptor (EGFR) mutation; Histology; Immunohistochemistry; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN 4;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER MORPHOLOGY; CANCER SURGERY; CANCER TISSUE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRONCHOSCOPY; CARCINOMA, SQUAMOUS CELL; ELECTROMAGNETIC PHENOMENA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; TRANSLOCATION, GENETIC;

EID: 84877893339     PISSN: 19446586     EISSN: 19488270     Source Type: Journal    
DOI: 10.1097/LBR.0b013e31828197e9     Document Type: Article

References (31)

1. Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3:122-133.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med. 2006;355:2542-2550.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
4. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment- by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6:64-70.
5. Bulman W, Saqi A, Powell CA. Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy. Am J Respir Crit Care Med. 2012;185:606-611.
6. Cooper WA, O'toole S, Boyer M, et al. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 2011;43:103-115.
7. Mukhopadhyay S. Utility of small biopsies for diagnosis of lung nodules: doing more with less. Mod Pathol. 2012;25(suppl 1):S43-S57.
8. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/ American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-128.
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
11. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-2388.
12. Cataldo VD, Gibbons DL, Perez-Soler R, et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364:947-955.
13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
14. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004-1012.
15. Gildea TR, Mazzone PJ, Karnak D, et al. Electromagnetic navigation diagnostic bronchoscopy: a prospective study. Am J Respir Crit Care Med. 2006;174:982-989.
16. Schwarz Y. Electromagnetic navigation. Clin Chest Med. 2010;31:65-73.
17. Makris D, Scherpereel A, Leroy S, et al. Electromagnetic navigation diagnostic bronchoscopy for small peripheral lung lesions. Eur Respir J. 2007;29: 1187-1192.
18. Eberhardt R, Anantham D, Herth F, et al. Electromagnetic navigation diagnostic bronchoscopy in peripheral lung lesions. Chest. 2007;131:1800-1805.
19. Eberhardt R, Anantham D, Ernst A, et al. Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial. Am J Respir Crit Care Med. 2007;176:36-41.
20. Wang Memoli JS, Nietert PJ, Silvestri GA. Metaanalysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest. 2012;142:385-393.
21. Wiener RS, Schwartz LM, Woloshin S, et al. Population- based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011;155: 137-144.
22. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
23. Edge SB, Byrd DR, Compton CC, et al, eds. Lung. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer; 2010. p. 253.
24. Travis WD, Brambilla E, Muller-Hermlink HK, eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. World Health Organization Classification of Tumours. Lyon: IARC Press; 2004. p. 9-122.
25. Cheung YC, Chang JW, Hsieh JJ, et al. Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle. Lung Cancer. 2010;67:166-169.
26. Garcia-Olive I, Monso E, Andreo F, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J. 2010;35:391-395.
27. Nakajima T, Yasufuku K, Suzuki M, et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest. 2007;132:597-602.
28. Navani N, Brown JM, Nankivell M, et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med. 2012;185: 1316-1322.
29. Solomon SB, Zakowski MF, Pao W, et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol. 2010;194:266-269.
30. Yang Y, Pan QJ, Teng MF, et al. Application of protein markers in combination with ThinPrep bronchial brush cytology in classification of lung cancer subtypes. Zhonghua Zhong Liu Za Zhi. 2008;30: 616-619.
31. Collins GR, Thomas J, Joshi N, et al. The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms. Cancer Cytopathol. 2012;120:134-141